Tom H Johnston

Tom H Johnston

UNVERIFIED PROFILE

Are you Tom H Johnston?   Register this Author

Register author
Tom H Johnston

Tom H Johnston

Publications by authors named "Tom H Johnston"

Are you Tom H Johnston?   Register this Author

49Publications

717Reads

31Profile Views

Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease.

J Pharmacol Exp Ther 2019 06 27;369(3):364-374. Epub 2019 Mar 27.

Atuka Inc., Toronto, Ontario, Canada (T.H.J., P.R., M.P.H., J.S., J.M.B., J.B.K.); Junaxo Inc., Toronto, Ontario, Canada (P.A.H.); and Krembil Research Institute, University Health Network, Toronto, Ontario, Canada (P.A.H., T.H.J., P.R., M.P.H., J.M.B., J.B.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.118.255695DOI Listing
June 2019

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Neuropharmacology 2019 03 1;147:11-27. Epub 2018 Jun 1.

Krembil Research Institute, University Health Network, Toronto, ON, Canada; Atuka Inc., Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2018.05.035DOI Listing
March 2019

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

J Pharmacol Exp Ther 2018 11 7;367(2):373-381. Epub 2018 Aug 7.

Adamas Pharmaceuticals, Inc., Emeryville, California (E.F.B., C.B., J.D.S.H., J.T.N.); Atuka Inc, Toronto, Ontario, Canada (T.H.J., M.P.H., P.A.H., J.M.B.); Krembil Research Institute, University Health Network, Toronto, Ontario, Canada (T.H.J., S.H.F., J.M.B.); and Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, Toronto, Ontario, Canada (S.H.F.)

View Article

Download full-text PDF

Source
http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.118.24
Publisher Site
http://dx.doi.org/10.1124/jpet.118.247650DOI Listing
November 2018

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Neuropharmacology 2018 03 29;131:116-127. Epub 2017 Nov 29.

Atuka Inc.,Toronto, ON, Canada; Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2017.11.046DOI Listing
March 2018

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Neuropharmacology 2015 Oct 10;97:306-11. Epub 2015 Jun 10.

Toronto Western Research Institute, University Health Network, 60 Leonard Ave., Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2015.05.033DOI Listing
October 2015

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.

Synapse 2015 Mar;69(3):99-102

Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada; Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/syn.21801DOI Listing
March 2015

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

Behav Pharmacol 2015 Feb;26(1-2):101-8

aToronto Western Research Institute bDivision of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/behaviouralpharm/2015/02000/L_7
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/FBP.0000000000000096DOI Listing
February 2015

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Neuropharmacology 2013 Oct 14;73:337-47. Epub 2013 Jun 14.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2013.06.005DOI Listing
October 2013

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit.

Mov Disord 2013 Oct 3;28(12):1675-82. Epub 2013 Sep 3.

Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama-Birmingham, Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25625DOI Listing
October 2013

RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.

Parkinsonism Relat Disord 2013 Feb 14;19(2):260-4. Epub 2012 Aug 14.

Division of Brain, Imaging & Behaviour, Systems Neuroscience, Toronto Western Research Institute, 399 Bathurst Street, MP-12-303, Toronto, ON M5T2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2012.07.001DOI Listing
February 2013

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.

Pharmacol Rev 2013 Jan 10;65(1):171-222. Epub 2013 Jan 10.

Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/pr.111.005678DOI Listing
January 2013

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

Neuropharmacology 2012 Oct 18;63(5):829-36. Epub 2012 Jun 18.

Toronto Western Research Institute, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2012.06.012DOI Listing
October 2012

A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.

Mov Disord 2012 Sep 13;27(11):1373-8. Epub 2012 Sep 13.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25133DOI Listing
September 2012

L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

J Pharmacol Exp Ther 2012 Aug 22;342(2):576-85. Epub 2012 May 22.

Toronto Western Research Institute, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/jpet.112.195693DOI Listing
August 2012

Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.

Mov Disord 2012 May 14;27(6):735-42. Epub 2012 Mar 14.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.24964DOI Listing
May 2012

5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.

Neurobiol Aging 2012 Jan 18;33(1):194.e5-15. Epub 2010 Jun 18.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2010.04.035DOI Listing
January 2012

Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.

Neurobiol Aging 2012 Jan 3;33(1):207.e9-19. Epub 2010 Nov 3.

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2010.09.011DOI Listing
January 2012

Experimental Models of l-DOPA-Induced Dyskinesia.

Int Rev Neurobiol 2011 ;98:55-93

Toronto Western Research Institute, Toronto, Ontario, Canada M5T 2S8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-381328-2.00003-1DOI Listing
January 2012

Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains.

J Neurosci Methods 2011 Apr 23;197(2):193-208. Epub 2011 Feb 23.

Centre for Neurobiology of Stress, Dept Biological Sciences, University of Toronto at Scarborough, 1265 Military Trail, Toronto, ON M1C 1A4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneumeth.2011.02.012DOI Listing
April 2011

Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism.

Neurobiol Dis 2011 Mar 21;41(3):591-604. Epub 2010 Oct 21.

Centre for Neurobiology of Stress, Dept. of Biological Sciences, University of Toronto, Scarborough, 1265 Military Trail, Toronto, ON, Canada M1C 1A4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2010.10.013DOI Listing
March 2011

The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.

Mov Disord 2010 Oct;25(13):2084-93

Division of Brain, Imaging, and Behaviour-Systems Neuroscience, Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23172DOI Listing
October 2010

Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.

Mov Disord 2010 Jul;25(10):1379-90

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23069DOI Listing
July 2010

Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations.

Mov Disord 2010 Jul;25(10):1399-408

Division of Brain Imaging & Behaviour Systems - Neuroscience, Toronto Western Research Institute,Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.23083DOI Listing
July 2010

New insights into the organization of the basal ganglia.

Curr Neurol Neurosci Rep 2009 Jul;9(4):298-304

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11910-009-0045-2DOI Listing
July 2009

Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.

Neuropharmacology 2008 Sep 27;55(4):483-90. Epub 2008 Jun 27.

Laboratoire de Neurobiologie de la Cognition, CNRS UMR 6155, Aix-Marseille Université, Case C, 3 Place Victor Hugo, 13331 Marseille Cedex 3, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuropharm.2008.06.038DOI Listing
September 2008

Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Mov Disord 2006 Nov;21(11):1879-91

Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.21073DOI Listing
November 2006

Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Mov Disord 2006 Jun;21(6):839-46

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.20828DOI Listing
June 2006

Drugs in development for Parkinson's disease: an update.

Curr Opin Investig Drugs 2006 Jan;7(1):25-32

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, MC 11-419, Toronto, ON M5T 2S8, Canada.

View Article

Download full-text PDF

Source
January 2006

Advances in the delivery of treatments for Parkinson's disease.

Expert Opin Drug Deliv 2005 Nov;2(6):1059-73

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON M5T 2S8, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425247.2.6.1059DOI Listing
November 2005

A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.

Exp Neurol 2005 Feb;191(2):243-50

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2004.10.002DOI Listing
February 2005

Drugs in development for Parkinson's disease.

Curr Opin Investig Drugs 2004 Jul;5(7):720-6

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
July 2004